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Abstract — Within national and international innovation 
systems a pandemic calls for large-scale action by many actors 
across sectors, in order to mobilise resources, developing and 
manufacturing Crisis-Critical Products as efficiently and in the 
huge quantities needed. Nowadays, this also includes digital 
innovations ranging from complex epidemiological models, 
artificial intelligence (AI) methodologies, to open data platforms 
for prevention, diagnostic and treatment.  
 
Amongst the many challenges during a pandemic, innovation 
stakeholders and manufacturing firms particularly find 
themselves suddenly engaged in new relationships, possibly even 
with firms that have been competitors prior to the pandemic. 
Those stakeholders are thus likely to face intellectual property (IP) 
related challenges. Unfortunately, to (governmental) decision 
makers these challenges might not appear to be of paramount 
urgency compared to the many, huge operational challenges to 
deploy urgently needed resources. However, if IP challenges are 
considered too late, they may cause delays to urgently mobilising 
resources effectively. Manufacturing firms could be reluctant to 
fully engage in the development and mass manufacturing of Crisis-
Critical Products. 
 
This paper adopts an IP perspective on the currently unfolding 
COVID-19 pandemic to identify pandemic related IP 
considerations and IP challenges. The focus is predominantly on 
individual challenges and technical aspects related to research, 
development and urgent upscaling of capacity to manufacture 
Crisis-Critical Products in the huge volumes suddenly in demand. 
Its purpose is to provide a structure for those concerned with 
steering clear of IP challenges to avoid delays in fighting a 
pandemic.  
 
From an ad-hoc patent analysis we identify that the majority of 
coronavirus related patents in the field are around organic 
chemistry, and development of methodologies and drugs for 
prevention, diagnosis and treatment of viruses. We also identify a 
time-lag between the outbreak and the materialisation of patent 
applications, which is consistent with the processes of the Patent 
Office. The large number of references to non-patent literature 
published after outbreaks is also an indication of the urgency of 
scientists to put the information in the public domain and make 
them accessible quickly to a wider audience. 
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We identify four stakeholder groups that are particularly 
concerned with IP related challenges during a pandemic. These 
include (i) governments, (ii) organisations owning existing Crisis-
Critical IP (incumbents in Crisis-Critical Sectors), (iii) 
manufacturing firms from other sectors normally not producing 
Crisis-Critical Products suddenly rushing into Crisis-Critical 
Sectors to support the manufacturing of Crisis-Critical Products 
(new entrants) in the quantities that far exceed incumbents’ 
production capacities and (iv) voluntary grassroot initiatives that 
are formed during a pandemic, often by highly skilled engineers 
and scientists to contribute to the development and dissemination 
of Crisis-Critical Products. 
 
This paper discusses IP challenges faced by those stakeholders 
during a pandemic related to the development and manufacturing 
of technologies and products for (i) prevention (of spread), (ii) 
diagnosis of infected patients and (iii) the development of 
treatments. We offer an initial discussion of potential response 
measures to reduce IP associated risks among industrial 
stakeholders during a pandemic. 
 
Keywords — Crisis, Pandemic, Intellectual Property, Licensing, 
Patent pledge, Compulsory Licensing, Patent Pools, Open Access, 
Incumbents, New Entrants, Coronavirus, COVID-19  
 
I. BACKGROUND 
 
A. The COVID-19 Pandemic 
 
In December 2019, an outbreak of a novel coronavirus in 
Wuhan, Hubei province, manifested itself as a global health 
tragedy. The World Health Organization (WHO) announced it 
as a public health emergency of international concern on 
January 30, 2020 [1] and as a pandemic on March 11, 2020 [2]. 
The virus, later named SARS-CoV-2 [3], can cause mild flu-
like symptoms (or even be asymptomatic) but can progress to 
acute pneumonia-like respiratory illness called novel 
coronavirus–infected pneumonia (NCIP). The overall clinical 
syndrome is known as COVID-19 [4].  Until today, there are no 
vaccines or medical cure for the disease yet [5] and the disease 
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has a fatality rate which is unconfirmed but likely to be around 
or above 1%. 
 
According to the Centre for Systems Science and 
Engineering (CSSE), Johns Hopkins University & Medicine, as 
of April 1, 2020 there were about 911,308 confirmed cases 
worldwide, 45,497 deaths and 190,710 recovered cases (Fig. 1). 
Currently, over 180 countries are affected. Most countries have 
seen exponential growth rates in the number of cases with Italy 
(13,155), Spain (9,053), the United States (4,484) France 
(3,523), and Mainland China (3,312) being the most affected 
countries in terms of number of deaths, as of April 1, 2020 [6], 
[7]. The virus has a stronger transmission capacity than the 
‘conventional’ annually recurring flu. On average, one infected 
person passes the virus to 2-2.5 others (that range is subject to 
change and can vary largely by geography, age group, and time) 
[8], [9]. 
 
The urgency of responding to the global threat of the 
pandemic has unleashed a plethora of efforts worldwide to 
tackle this pandemic as quickly as possible. Health care remains 
the utmost priority. Among other activities, research, 
technology and innovation efforts are pouring in to support 
health care systems through the development and ramping up 
the manufacturing of Crisis-Critical Products (CC-Products), 
such as Personal Protection Equipment (PPE), diagnostics tests, 
treatments, ventilators, vaccines etc.  
 
While this calls for existing manufacturers (incumbents) that 
operate in Crisis-Critical Sectors (CC-Sectors) to quickly ramp 
up their production capacities, this also draws various other 
organisations into CC-Sectors that have not produced CC-
Products prior to the pandemic. These ‘new entrants’ include 
large manufacturing firms from related and non-Crisis-Critical 
Sectors (CC-Sector), but also voluntary initiatives, not-for-
profit organisations, scientists, engineers, universities, research 
institutions, start-ups and other forms of grassroots initiatives, 
etc., within the CC-Sector. Open Innovation efforts involving 
incumbents and new entrants become essential to address crisis-
critical challenges. Incumbents typically own Crisis-Critical 
background IP (CC-IP) relevant for the manufacturing of CC-
Products that new entrants lack. On the other hand when 
engaging in open innovation for the development and 
manufacturing of CC-Products, new entrants are likely to 
develop potentially valuable foreground CC-IP during the 
pandemic. 
 
The purpose of this first paper is two-fold. First, we hope it 
contributes to raising awareness that IP considerations need to 
be addressed early rather than later during a pandemic. Second, 
we provide a structure (if not conceptual framework) for those 
concerned with steering clear of IP challenges, e.g. policy 
makers, governments, international organisations, large IP 
owners, new entrants, but also the many voluntary initiatives 
that are part of the grassroots movement. 
 
This paper contributes to the many efforts to contain the 
pandemic as quickly as possible. We explore relevant IP 
considerations, provide a relevant terminology, describe the 
patent landscape of coronaviruses, systematically conceptualise 
Fig. 1 COVID-19 spread (Source: Bloomberg, https://www.bloomberg.com/graphics/2020-coronavirus-cases-world-map/, 01.04.2020 
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three scenarios with different IP considerations and provide an 
initial discussion of possible approaches to reduce IP associated 
risks for relevant stakeholders, thus ensure that IP 
considerations do not delay the fight against a pandemic.  
 
We apply an IP and innovation perspective on the enfolding 
pandemic and provide a systematic compilation, description 
and analysis of IP issues of relevance related to three critical 
areas for fighting the COVID-19 pandemic: (i) prevention of 
further spreading, including vaccine development, (ii) the 
development of diagnostics (i.e. test kits) for determining 
whether persons are infected or not and (iii) the (development 
of) treatments, i.e. a preventative-diagnostic-treatment 
framework.  
 
B. Technology Related Pandemic Challenges 
 
Applying an innovation and IP perspective we particularly 
focus on five technology related challenges that emerged from 
observations during the recent weeks of the pandemic, some 
relate to novel technologies highlighted in the WHO’s 
Coordinated Global Research Roadmap for COVID-19 [10] 
while other have emerged from operations needs in frontline 
healthcare.  
 
First and foremost, the challenge of finding a treatment for 
the acute respiratory pneumonia caused by COVID-19 has 
initiated large-scale R&D efforts. Second, the pandemic has 
created a sudden and massive demand for the development and 
manufacturing in extremely large volumes of diagnostic testing 
kits, not only with high accuracy that can be conducted in high 
capacity (e.g. for several weeks Germany alone has carried out 
160,000 tests per week [11]) but also new ways of organising 
testing to be done (e.g. COVID-19 isolation pods, drive through 
testing).  Third, the pandemic caused a sudden need to treat a 
large number of patients in hospitals requiring an 
extraordinarily large ICU capacity, particularly with an 
enormous need for certain medical devices particularly 
ventilator capacity (e.g. UK ventilator challenge [12]) by far 
exceeding the currently available capacity in many hospitals 
and countries. Fourth, the pandemic has called for a need of 
digital innovation, including epidemic modelling to monitor 
and understand the spread and development of the virus across 
populations, including tracking of cases and spreaders. Fifth, 
the COVID-19 pandemic has caused an exceptional high 
demand for skilled medical staff, doctors and nurses, 
particularly with ICU experience, such as anaesthetists and 
critical care nurses, all of whom need to be equipped with PPE 
(personal protective equipment), in this pandemic particularly 
protective clothing, face shields, goggles, gloves to protect 
health care staff from infection. 
 
Additional challenges not addressed in this paper include the 
security of supply chains for essential goods; the impact of 
drastically reduced passenger and cargo transport routes and 
innovating at a health systems and infrastructure level to cope 
with testing and treating huge numbers of people.   Also, the 
securing of food supply (chains) with supermarket chains play 
a major role, including the optimisation of delivery route 
planning, quick adjustments to online booking systems, e.g. 
rationing certain goods or prioritising delivery slots to the 
elderly and vulnerable. Other challenges then relate to the 
Information Technology (IT) and infrastructure for connecting 
all the people suddenly trying to work at home, i.e. video 
conferencing platforms and equipment (e.g. Google and 
Microsoft announced free access to their advanced tele-
conferencing and collaboration tools [13] as well as internet 
service providers relieving data caps [14]). And then there are 
urgent logistical challenges, for instance, to efficiently 
reorganise supply of Crisis-Critical Products (CC-Products), 
the repatriation of national citizens stuck abroad, but also 
internal operations processes in hospitals as wards have been 
repurposed and specific COVID-19 testing pods have been 
setup. This list is obviously not exhaustive. 
 
C. Innovative and Technology Responses to the Pandemic 
 
During the past weeks we have observed a number of 
responses to the five challenges outlined above. 
Pharmaceutical, biotechnology firms and universities have 
joined forces to develop vaccines [15] and treatments [16], also 
testing whether existing antiviral drugs could be repurposed, 
e.g. malaria / HIV drugs or the development of novel COVID-
19 specific drugs [17]. For instance, a collaboration of Clover 
and GSK has been announced recently [18]. Another 
consortium includes life big Pharmaceutical companies such as 
Novartis, Bristol Myers Squibb and GSK [19]. Others started to 
develop novel diagnostic test, such as BOSCH recently having 
announced they had developed their own COVID-19 test kit 
[20]. Manufacturing companies from all kind of sectors have 
started to repurpose their production lines to support the 
production of Crisis-Critical Products, involving large 
engineering / manufacturing firms such as those involved in the 
UK ventilator challenge consortium (e.g. Airbus, GKN, Roll-
Royce, Siemens, Smiths group) [12], [21], [22], but also luxury 
brands (e.g. French LVHM) using perfume manufacturing 
facilities to suddenly make hand sanitisers [23], as well as 
SMEs starting to produce sanitisers [24],  textile manufacturers 
(e.g. ZARA in Spain [25], Trigema in Germany [26], Prada in 
Italy [27]) to produce face masks. Various volunteering 
initiatives started to emerge run by scientists and engineers to 
(i) develop open hardware / source designs of ventilators, (ii) 
find new ways of design and manufacture PPE, e.g. 3D printed 
face shields [28] and ventilator valves [29]. 
 
Last but certainly not least, digital innovations have sprung 
up widely, e.g. data / software approaches by scientists for 
prevention, diagnostic and treatment. Focusing on preventative 
digital innovation, scientists have focused more on open data 
platforms, by developing epidemiological models to understand 
government responses and forecast the growth curves of the 
virus [31], analysing geospatial models to understand the 
distribution and spread of the virus [32], and deploying causal-
effect models to understand symptoms of the virus and limit its 
spread through behavioural science, and tracking applications 
[33]. In the diagnostic sphere, scientists utilise AI, and more 
specifically Deep Convolutional Neural Networks to detect 
COVID-19 from X-Ray Images. This has also been particularly 
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useful in diagnostic analysis of symptoms to predict the 
development of a patient’s case [34]. A high number of efforts 
have also been concentrated on treatments, where scientists 
have developed AI text and data mining tools to help the 
medical community develop answers to high priority scientific 
questions and potential treatments. Efforts have focused on the 
development and summarisation of genome specific medical 
protocols of precision medicine and host response, as well as 
modelling and simulation of the virus propagation and 
efficiency of interventions [35]. 
 
From what emerged during this pandemic in the news and 
expert discussions, one can categorize the crisis-critical 
activities in three categories, most of them related to innovation 
or massive capacity building / upscaling to manufacture and 
supply CC-Products in sufficient quantities in a short period of 
time. The first category is prevention, including digital 
innovations to track the virus spread, sanitisers, PPE equipment 
etc in order to slow down the spread of the virus, but also 
vaccines to control future outbreaks which are currently under 
development. The second category is diagnostics 
predominantly including the need for an incredible volume of 
testing kits, and those that are accurate, but also portable and 
deliver speedy results, recently also antibody tests. The third 
category is treatment, including development of treatments 
through repurposing or existing drugs, development of new 
antiviral drugs, but also ventilators for ICU critical care in 
hospitals around the world. Those three categories are used 
throughout the remainder of this paper. 
 
II.  WHY WORRY ABOUT IP DURING A PANDEMIC 
 
A general characteristic of IP is that it is intangible and 
remains largely invisible in most day to day operations of 
companies and economies. Yet, it is vital for the functioning of 
today’s economy in normal but likewise in times of crisis.  
 
For the purpose of this paper we define “Crisis-Critical IP” 
(CC-IP) as the set of intellectual property, relevant for the 
research, development, manufacturing and distribution of 
Crisis-Critical Products, Services and Technologies that are 
urgently needed for quickly ending a crisis situation, with crisis 
defined as a situation, that threatens the human species and an 
approved world body elevates the risk as critical, i.e. in the case 
of COVID-19 the WHO has declared this situation a pandemic. 
CC-IP includes (i) formal and registered IP, such as patents, 
design rights, trademarks, (ii) formal unregistered IP, e.g. 
copyrights, design drawings, CAD files, trade secrets for 
manufacturing processes, as well as (iii) informal IP, such as 
know-how. CC-IP refers both to already existing (background) 
IP predominantly owned by incumbents that already operate in 
CC-Sectors prior to a crisis as well as novel (foreground) CC-
IP that is developed during the crisis by various kind of actors, 
including incumbents, but also new entrants to CC-Sectors.  
 
Certain CC-Sectors and its related technologies, products and 
services have different degrees of formal and informal IP. Some 
of these products are more ‘high-tech’ than others. Previous 
studies show that IP appears to be of particular importance in 
certain sectors, such as electronics, ICT, high value 
manufacturing, software, but also pharmaceutical, 
biotechnology, medical devices and life sciences. Many of 
those IP intensive sectors are of particular relevance in today’s 
unfolding pandemic. For instance, ventilators are typically 
expensive medical devices and the incumbent manufacturing 
companies are likely to own alive / active (i.e. not yet expired) 
CC-IP, PPE equipment (e.g. face masks) being fairly ‘low tech’, 
with a high probability that formally relevant CC-IP has 
expired.  
 
While IP issues have hardly surfaced during the beginning of 
this pandemic, this has happened quite recently. A few 
examples are summarised below. The Wellcome Trust appears 
to be among the first prominent organisations that understood 
the relevance of IP for this pandemic early on [36]. With a 
particular focus on research, on January 31, 2020, the trust 
called for journals, publishers etc. to allow widespread sharing 
of all potentially relevant research and dataset. This initiative is 
geared towards publishers to not put any COVID-19 relevant 
publications behind a paywall. The pledge seems to be a huge 
success as a wide range of renowned organisations have now 
signed up to it, including leading journals, such as Nature and 
The Lancet, but also the European Commission, publishers (e.g. 
Cambridge University Press), national academies of science 
(e.g. Academy of Medical Sciences, The Royal Society), 
foundations (e.g. Bill & Melinda Gates Foundation), research 
councils (e.g. UK Medical Research Council), ministries (e.g. 
Indian Department of Biotechnology, Ministry of Science & 
Technology) and a wide range of other organisations, including 
companies (e.g. BenevolentAI, Johnson & Johnson). By now 
more than 24,000 research papers are available online [37]. In 
the past weeks some other organisations have started raising 
concerns that IP might be an issue during the pandemic and 
have called for the government and private sector to respond. 
For instance, on March 27, 2020, Doctors Without Borders 
(MSF) publicly announced their concern that firms might try to 
profiteer from the crisis [38] and the government of Costa Rica 
called the WHO to organise the pooling of relevant IP [39]. By 
now, a few governments have passed compulsory license 
resolutions for CC-IP, e.g. Chile and Canada [40] and some 
even authorized issuance of compulsory license  e.g. Israel’s 
compulsory licensing for Kaletra [41]. Compulsory licensing 
schemes are typically some kind of “last resort” government 
measures.  
 
We have also observed some initial approaches that firms 
have taken related to IP during this pandemic. For instance, 
measures to mitigate the risk of counterfeit products being 
distributed in the crisis, e.g. PPE masks [42], [43]. Some 
companies enforced IP lawsuits against other companies 
developing CC-Products. For instance, Labrador Diagnostics 
LLC sued BioFire, a company developing COVID-19 testing 
kits for infringing two of its patents [44],but later announced a 
royalty free licensing to anyone developing tests [45]. Some 
first firms have already filed patents or other forms of 
exclusivity, e.g. Gilead applied for “orphan drug” designation, 
but dropped it a few days later after criticism [46], Pharma firms 
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filed for repurposing of drugs extending indications e.g. 
Remdevir [46], [47].  
 
Very recently we have seen a limited number of firms 
adopting at least some selective open IP approaches, 
particularly pledging [48] relevant IP, such as Fortress [49], 
AbbVie and medical device companies manufacturing 
ventilators sharing IP (including design specifications and 
files), such as Irish Medtronic [50] and UK based Smiths 
Group  [51]. A recent initiative of scientists and lawyers has 
launched the Open COVID Pledge 
(www.opencovidpledge.org) calling IP owners to not assert 
relevant IP during the crisis until one year after the WHO 
declares the pandemic to be over [52]–[54]. 
 
III. CORONAVIRUS PATENT ANALYSIS 
 
One of the main IP challenges, both in this pandemic, and in 
general is the availability of open data for analysing the 
progression of the virus [55], as well as the different analysis 
types deployed [56]. In an outbreak so severe as the COVID-
19, where the reported cases to this moment are close to 1 
million worldwide, any available dataset is potentially helpful 
to derive insights into the disease. We perform an ad-hoc patent 
analysis for coronaviruses using an open dataset by Lens.org1, 
to enhance our understanding into preventive, diagnostic and 
treatment measures for the virus. We focus on the broader 
spectrum of coronaviruses to identify patterns from earlier 
outbreaks that could be applied in the case of COVID-19. Table 
1 shows the descriptive statistics and correlations for the patent 
dataset and Fig.2 shows some initial results from the 
Coronavirus Patent Analysis.  
 
Fig. 2a shows the top 10 CPC classification distribution at 
the subgroup level. It is evident that the highest number of 
patents belonging to the primary CPC subgroup classification 
are in C07K14/005. This is the organic chemistry subclass, for 
peptides with more than 20 amino acids and specifically for 
viruses, which constitute viral proteins. This is followed by the 
subgroups A61K39/215 (medicinal preparations containing 
antigens or antibodies materials for immunoassay for 
coronavirus) and C12Q1/701 (measuring or testing processes 
involving enzymes, nucleic acids or microorganisms involving 
virus specific hybridization probes). These are followed by 
C12N7/00 (preparation of viruses bacteriophages 
compositions, medicinal viral antigen or antibody 
compositions), G01N1 (investigation processes for measuring 
or testing other than immunoassay, involving enzymes), 
C07K16/08 (investigation of immunoglobulins from RNA 
viruses). Within the top 10 classes, we also find a subclass 
within section Y (Emerging Cross-Sectional Technology), with 
Y02A50/451, which is specific for genetic or molecular 
screening of pathogens. This indicates that within the granted 
patents, there are some vaccination related patents available. 
All the top 10 CPC classifications have to do specifically with 
the chemical characteristics of the virus for prevention, 
 
1 Human Coronavirus Innovation Landscape: Patent and Research Works 
Open Datasets. Accessed 01.04.2020 at https://about.lens.org/covid-19  
diagnostics and treatment. Also, one could note that granularity 
of patent applications in these fields since some of these have 
50 CPC subgroups. 
 
Fig. 2b shows the top 10 IPC classification distribution at the 
subgroup level. There are 103 unique subgroups referenced 
within these patents. While the highest primary IPC sub group 
is A61K39/215 (preparation for medical purposes devices or 
methods specially adapted for bringing pharmaceutical 
products into particular physical or administering forms 
chemical aspects of, or use of materials for deodorisation of air, 
for disinfection or sterilisation, or for bandages, dressings, 
absorbent pads or surgical articles  soap compositions for 
coronavirus), the highest collective number is for the subgroup, 
C12N15/09 (microorganisms or enzymes compositions thereof 
propagating, preserving or maintaining microorganisms 
mutation or genetic engineering culture media microbiological 
testing media recombinant DNA-technology).  
 
Moreover, 64% of the top 10 IPC subgroups, fall within the 
A61K subclass [57], which covers the following subject matter 
under a mixture composition or process of preparing a 
composition or treating process: drug or other biological 
compositions which are capable of: preventing, alleviating, 
treating or curing abnormal or pathological conditions of the 
living body by such means as destroying a parasitic organism, 
or limiting the effect of the disease or maintaining, increasing, 
decreasing, limiting, or destroying a physiological body 
function; diagnosing a physiological condition or state by an in 
vivo test; in vitro testing of biological material. The rest of the 
subclasses fall within the C12 class, where viruses, 
undifferentiated human, animal or plant cells, protozoa, tissues 
and unicellular algae are considered as microorganisms. From 
both Fig.2a and Fig.2b, it appears evident that the highest 
clusters of patents are around the chemical process of 
identification, composition and vaccine development for the 
coronavirus family. 
 
Fig. 2c shows the distribution of patent applications within 
the different jurisdictions. Fig.2d shows the distribution of the 
granted patents within different jurisdictions. Immediately, 
evident is that the granted patents are lagging behind the patent 
applications. There are some old granted patents that fall within 
the broad spectrum of the analysis in 1975 about the 
development of vaccines, however patent applications before 
1975 are not included in the dataset. The majority of patent 
applications are filled in the US, followed by the transition to 
WO under the Patent Cooperation Treaty (PCT). These are 
followed by AU, CN, EP, CA, KO and JP. The distribution of 
granted patents follows an upwards trend (greater rate of 
increase than that of patent applications), but with significantly 
lower numbers (with the peak around 120 granted patents in 
2019 relative to an average of 300 patent applications from 
Fig.2c). The distribution of these granted patents within the 
different jurisdictions are US, EP, AU, CN, KO, RU, and JP. It 
is also interesting to note that the conversion rate of patent 
applications to granted patents is 32%. 
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   Table 1 D
escriptive Statistics and Correlations for Coronavirus: Broad K
eyw
ords Based Patents (Patents = 6896, Patent Fam
ilies = 2670) 2 
 
Publication 
Y
ear 
A
pplication 
Y
ear 
Earliest 
Priority Y
ear 
N
um
ber of 
A
pplicants 
N
um
ber of 
Inventors 
Forw
ard 
C
itations 
Sim
ple  
Fam
ily Size 
Extended 
Fam
ily Size 
Sequence 
C
ount 
N
o. of C
PC
 
Subgroups 
N
o. of IPC
 
subgroups N
PL C
itation 
C
ount 
M
ean 
2010 
2008 
2007 
1.99 
3.78 
4.78 
13.81 
20.58 
465.78 
5.97 
5.88 
5.62 
Std. Error 
0.08 
0.08 
0.08 
0.02 
0.03 
0.20 
0.17 
0.57 
156.48 
0.06 
0.08 
0.23 
M
edian 
2011 
2008 
2006 
1.00 
3.00 
0.00 
9.00 
11.00 
0.00 
3.00 
4.00 
0.00 
M
ode 
2005 
2004 
2003 
1.00 
2.00 
0.00 
2.00 
2.00 
0.00 
3.00 
3.00 
0.00 
Std. D
ev. 
6.33 
6.55 
6.53 
1.99 
2.48 
16.81 
14.18 
47.58 
12994 
5.20 
6.20 
19.27 
K
urtosis 
1.09 
0.93 
0.93 
13.67 
7.01 
313.38 
4.12 
318.23 
1354.76 
9.65 
19.00 
66.04 
Skew
ness 
-0.78 
-0.65 
-0.60 
3.10 
2.30 
13.22 
1.87 
14.88 
35.86 
2.60 
3.22 
6.76 
M
in. 
1975 
1973 
1972 
0.00 
2.00 
0.00 
1.00 
1.00 
0.00 
3.00 
0.00 
0.00 
M
ax. 
2020 
2020 
2020 
18.00 
22.00 
555.00 
117.00 
1173.00 
544026.00 
56.00 
103.00 
342.00 
C
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ear 
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Earliest Priority Y
ear 
0.91 
0.96 
1 
  
  
  
  
  
  
  
  
  
N
um
ber of A
pplicants 
-0.09 
-0.04 
-0.04 
1 
  
  
  
  
  
  
  
  
N
um
ber of Inventors 
0.12 
0.12 
0.13 
0.36 
1 
  
  
  
  
  
  
  
Forw
ard C
itations 
-0.21 
-0.18 
-0.17 
0.12 
0.00 
1 
  
  
  
  
  
  
Sim
ple Fam
ily Size 
-0.01 
-0.08 
-0.15 
-0.05 
-0.01 
0.03 
1 
  
  
  
  
  
Extended Fam
ily Size 
-0.05 
-0.07 
-0.11 
0.03 
0.03 
0.12 
0.34 
1 
  
  
  
  
Sequence C
ount 
0.02 
0.02 
0.03 
0.03 
0.01 
0.00 
-0.02 
-0.01 
1 
  
  
  
N
o. of C
PC
 Subgroups 
-0.10 
-0.10 
-0.13 
0.12 
0.05 
0.14 
0.00 
0.05 
0.04 
1 
  
  
N
o. of IPC
 subgroups 
-0.21 
-0.26 
-0.29 
-0.02 
0.00 
0.07 
0.26 
0.12 
-0.01 
0.20 
1 
  
N
PL C
itation C
ount 
0.10 
0.08 
0.05 
0.07 
0.04 
0.10 
0.04 
0.05 
0.00 
0.05 
0.00 
1 
N
ote: Search Q
uery:  (title:(C
oronavirus) O
R abstract:(C
oronavirus) O
R claim
s:(C
oronavirus)) O
R (title:("Severe acute Respiratory syndrom
e") O
R abstract:("Severe acute Respiratory syndrom
e") O
R 
claim
s:("Severe acute Respiratory syndrom
e")) O
R (title:("coronaviridae") O
R abstract:("coronaviridae") O
R claim
s:("coronaviridae")) O
R claim
s:("SARS-C
oV") O
R claim
s:("M
ERS-C
oV") O
R claim
s:("C
O
VID
 
19") O
R claim
s:("W
uhan coronavirus") O
R claim
s:("2019-nC
oV") O
R claim
s:("M
iddle East respiratory") 
    
2 H
um
an C
oronavirus Innovation Landscape: Patent and R
esearch W
orks O
pen D
atasets. A
ccessed 01.04.2020 at https://about.lens.org/C
O
V
ID
-19  
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(a) Top 10 CPC Classification Distribution 
(sorted by descending order of primary CPC main group) 
 
 
(b) Top 10 IPC Classification Distribution 
(sorted by descending order of primary IPC main group) 
 
  
 
(c) Patent Applications Distribution  vs. Publication Year 
(filter by jurisdiction) 
 
 
(d) Granted Patents Distribution vs. Publication Year 
filter by jurisdiction 
 
  
 
(e) Top 10 Applicants 
(co-applications are also included in the above data) 
 
 
(f) Distribution of Patent Characteristics vs. the Publication Year 
 
 
Fig. 2 Results from the Coronavirus Patent Analysis 
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IV. IP CONSIDERATIONS DURING A PANDEMIC 
 
What in normal circumstances are considered typical IP 
activities are no more normal during times of pandemics. In this 
‘new normal’, our analysis about the IP related considerations 
that arise during the efforts to end the COVID-19 pandemic 
identifies scenarios with IP relevance involving four main 
stakeholder groups shown in  
 
Our analysis finds that during the COVID-19 pandemic a 
range of non-Crisis-Critical Product (CC-Product) 
manufacturers entered Crisis-Critical Sectors (CC-Sectors), in 
which incumbent manufacturers have developed, produced and 
supplied Crisis-Critical Products (CC-Products) already before 
the pandemic. Those existing firms had insufficient production 
capacities to supply Crisis-Critical Products (CC-Products) in 
the huge quantities needed in a timely manner, leading to supply 
shortages for customers. Firms from non-Crisis-Critical Sectors 
(CC-Sectors), such as 3D printing, automotive, aerospace, 
home appliances, fashion and luxury goods, rushed into CC-
Sectors to help cope with the CC-Product supply shortages 
 
 
 
Fig. 3 Four Main Stakeholder Groups that are concerned with IP during 
a Pandemic 
Table 2 provides an overview of the IP related considerations 
for COVID-19 (with examples) distinguishing (i) the 
prevention of COVID-19 (including measures to limit its spread 
and vaccines to prevent future outbreak), the (ii) diagnostics 
(including professional and self-testing) and (iii) treatment, 
with the latter including the direct treatments (e.g. development 
of drugs) but also the treatment of symptoms, i.e. related to the 
medical equipment needed to keep bodies alive (e.g. ventilators, 
ICU beds). 
 
The following conceptual scenarios are built on the 
distinction between these groups of stakeholders. First, we label 
firms as ‘incumbents’ that already operated in CC-Sectors 
before the start of the pandemic developing, manufacturing and 
supplying CC-Products. These incumbents are highly likely to 
own CC-IP when a pandemic starts. Second, we label those 
organisations ‘new entrants’ that suddenly rush to enter the CC-
Sectors after the beginning of a pandemic in order to support 
scaling up the development and manufacturing of CC-Products. 
New entrants can be industrial manufacturing firms (Type 1), 
but also voluntary grassroot initiatives, including not-for-profit 
communities, start-ups, entrepreneurial scientists, etc (Type 2). 
While manufacturing firms entering CC-Sectors are highly 
likely to own IP, this might not be relevant CC-IP. In contrast, 
voluntary grassroot initiatives typically do not own formal IP 
prior to a pandemic as these only form during a pandemic. 
Based on that distinction we identify three broad scenarios that 
are discussed below. 
 
A. Scenario 1: Type 1 New Entrants – Non CC-Product 
Manufacturers 
 
Existing, often large manufacturing firms that did not 
produce CC-Products before the start of a pandemic are (i) 
either called in (ordered) to help with upscaling the production 
of CC-Products by governments (e.g. UK government’s call for 
firms to produce ventilators [12], [92]) or (ii) voluntarily switch 
their production to CC-Products, e.g. because their usual 
products are not in demand during the pandemic (e.g. luxury 
company LVHM starting to produce health care products like 
sanitisers, hydroalcoholic gel [93]). These firms then become 
new entrants into CC-Sectors. There appears to be four kinds of 
new entrants that suddenly rush to help with producing CC-
Products by repurposing their production lines.  
 
First, despite coming from different sectors, certain 
specialized companies at least have manufacturing capacity as 
well as a set of valuable resources and capabilities that are 
somewhat related and can be readily used with a minimal 
change for production of certain CC-Products to meet the 
supply shortage. Examples include companies such as LVHM, 
which had been producing perfumes before the COVID-19 
pandemic, so own manufacturing process equipment to fill 
bottles with alcohol containing liquid. During the pandemic 
they changed the liquid from perfume to sanitiser.  
 
The second type of manufacturing companies are those that 
possess relevant expertise, resources and competence that can 
be put in use for developing and manufacturing CC-Product to 
address a shortage of certain CC-Products. An example is the 
UK company Dyson, which has long been in the air-flow 
business for its vacuum cleaners and hair dryers, has expertise 
in air purification technologies with some of its technologies 
like its digital motor already optimized for safety and 
efficiency. Dyson hence was able to develop a new ventilator 
design called CoVent in just 10 days [78]. Another example is 
GENTL masks, an open source design for masks by EPAM, an 
engineering and software solution provider and platform 
developer [65] 
 
The third type includes technology giants that possess 
diverse capabilities and rich resources that they can deploy to 
basically manufacture any product using IP from incumbents in 
the CC-Sectors. Those include automotive companies entering 
the production of ventilators (e.g. Volkswagen [94]), but also 
multinationals like BOSCH starting to produce diagnostic test 
kits [20]. 
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Table 2 IP Considerations for CO
V
ID
-19, synthesized w
ith an adapted Intellectual Property (IP) Roadm
apping Fram
ew
ork 
Table 2a: IP Considerations for Technologies, Products, Services, IP Ecosystem
, Purpose and Challenges 
C
O
V
ID
-19 
Prevention 
D
iagnostics 
Treatm
ent 
Why? 
Technologies, products, services 
Which technologies are relevant? What 
types are these? How are important 
platforms developing? 
V
accine: 
1) V
accines to prevent future outbreak (Table 3) [58]–[60] 
2) Tools to m
onitor the spread of the disease [61] 
3) Epidem
iological m
odels to forecast the grow
th curves) [31] 
4) A
nalysis of geospatial data of C
O
V
ID
-19 cases [33] 
5) C
ausal Effects and in-depth analysis of C
O
V
ID
-19 causes, and 
effects, sym
ptom
s; A
pplying m
achine learning/A
I m
ethods to m
itigate 
the spread of the C
O
V
ID
-19 [62] 
M
edical equipm
ent / PPEs: 
1) D
iagnostics kits  ([63], [64] for list of approved rapid and other 
C
O
V
ID
-19 test-kits) 
2) M
asks to prevent disease spread ([66] for list of D
IY
 m
asks) 
3) Sanitizers to avoid spreading of disease [67]–[69] 
4) Specialized products to avoid spreading of disease [70] 
M
edical equipm
ent/ m
ethods: 
1) Testing kits (Self-testing kit/ 
Professional testing kit): 
2) H
om
e testing-kit [71] 
3) R
apid testing technology [72] 
(e.g.[63], [64] for list of approved 
rapid and other C
O
V
ID
-19 test-kits) 
4) A
I tools - D
etection of C
O
V
ID
-19 
using D
eep C
N
N
s from
 X
-R
ays [34] 
5) D
iagnostic analysis and 
forecasting of sym
ptom
s  [73] 
D
rugs: 
1) Existing drugs that can potentially treat C
O
V
ID
-19 (repurposing) -  rem
desivir, 
lopinavir and ritonavir in com
bination; lopinavir/ ritonavir plus interferon-beta; 
and chloroquine and hydroxychloroquine [74] 
2) G
enom
e-specific C
O
V
ID
-19 m
edical protocols, including precision m
edicine  
3) M
odeling, sim
ulation, of C
O
V
ID
-19 propagation and efficacy of interventions 
[73] 
4) D
esign and sharing of clinical trials for analysis on m
edications, and therapies 
[62] 
5) D
evelop A
I text and data m
ining tools that can help the m
edical com
m
unity 
develop answ
ers to high priority scientific questions about treatm
ents [35]  
M
edical equipm
ent: 
1) V
entilators (lightw
eight / portable) valves [22][29] 
2) M
edical grade m
asks [27] 
 
Who and what? 
IP ecosystem stakeholders 
Consider the different IP ecosystem actors. Which actors are likely to 
play important roles? Which roles do they play? 
Incum
bents from
 C
C
-Sectors: 
M
edical technology &
 tool developers: 
1) Traditional health incum
bents develop test-kits (Everyw
ell [71]) 
2) D
igital health com
m
unity develop digital tools to m
onitor spread [61] 
3) B
ig pharm
a and drug developm
ent firm
s: G
SK
, J&
J, G
ilead, Zydus 
C
adila, [18], [75] 
M
edical and healthcare service providers: 
1) Testing service providers (telem
edicine doctors), PW
N
H
ealth [71]  
U
niversities and research institutions: 
1) U
niversities (vaccines, sanitizers) (e.g., O
xford's vaccine [76], IIT 
D
elhi's Sanitizer)  
N
ew
 entrants from
 non C
C
-Sectors  (N
ew
 entrant type 1): 
1) Engineering and softw
are solution providers offer open source 
designs for m
asks (e.g. G
EN
TL m
ask, open source by EPA
M
 [65]) 
2) IT giants give free platform
 access to support rem
ote w
orking [13] 
3) 3D
 printing developm
ent, hands-free door handle attachm
ents [70] 
Incum
bents from
 C
C
-Sectors: 
M
edical technology &
 tool 
developers: 
1) C
C
-Sector incum
bents  
2) U
niversities (E.g., O
xford's rapid 
testing technology)  [72] 
M
edical and healthcare service 
providers: 
1) Testing service providers 
(telem
edicine doctors), PW
N
H
ealth 
[71]  
 
Incum
bents from
 C
C
-Sectors: 
D
rug developers:  
1) B
ig pharm
aceutical com
panies: G
SK
, N
ovartis, B
ristol M
yers Squibb, A
bbV
ie 
[19] 
M
edical technology &
 tool developers: 
1) D
igital health com
m
unity w
ith tools for treatm
ent [61] 
U
niversities: 
1) U
niversity start-ups m
ake portable ventilators (e.g. U
niversity of Toronto) [77] 
N
ew
 entrants from
 non C
C
-Sectors: 
1) 3D
 printing com
panies prototyping and m
anufacturing ventilators and valves 
[29] 
2) A
erospace and autom
otive industry into ventilator m
anufacturing [12], [21], 
[22] 
3) H
ousehold appliances industry (e.g. D
yson's C
oV
ent applying D
yson's air 
purifier expertise to ventilators) [78] 
4) Fashion industry for m
edical m
asks (e.g.  Zara [25], Trigem
a [26], Prada [27]) 
 
Start-ups from
 C
C
-Sector (N
ew
 entrant type 2): 1) Start-ups developing testing solutions &
 partnering w
ith m
edical centres (blood testing by Sight D
iagnostics, Israel start-up w
ith Sheba M
edical)[79] 
N
ew
 entrants from
 non C
C
-Sectors (N
ew
 entrant type 1): 1) Publishers providing free access to research and technologies (e.g. Springer N
ature, PubM
ed C
entral, A
ssociation of A
m
erican Publishers, 
IEEE [37], [80], [81])  
Platform
 creators/integrators: 1) Platform
s to pledge IP (e.g., O
pen C
ovid pledge) [52]–[54] 
C
harity organizations: 1) R
esearch charity organizations and foundations (e.g., W
ellcom
m
e trust, B
ill and M
elinda G
ates Foundation [82]) 
G
overnm
ent bodies: 1) W
H
O
 (e.g. provides standard for sanitizers,  asked to create patent pools); 2) N
ational governm
ents (announcing and considering com
pulsory licensing) [74]; 3) G
overnm
ent-
industry engagem
ents (e.g. Johnson &
 Johnson expanded an existing R
&
D
 agreem
ent w
ith the U
S D
epartm
ent of H
ealth and H
um
an Services (H
H
S) to develop C
O
V
ID
-19 vaccine) [83] 
 
IP purpose 
What purpose 
does IP Serve? 
1) A
ddressing supply shortages of M
asks. Free design / D
IY
s free up the 
dem
and for clinical grade m
asks for use in hospitals [66] 
2) A
ccess to critical and relevant know
ledge  and social aw
areness 
through copyrights w
aiver and offering free contents [37], [80], [81] 
3) A
ccelerating vaccine developm
ent through consortium
s and IP 
pooling and expertise [84] 
A
ccelerated developm
ent and w
ider 
availability of testing kits through IP 
sharing [35] 
1)W
ider accessibility of m
edicines through access to patents (e.g., A
bbV
ie has 
agreed to drop enforcem
ent of K
aletra patents w
orldw
ide) [85] 
2) A
ddressing supply shortages in ventilators, V
entilator C
hallenge U
K
 
consortium
 [22] 
3) A
ccelerated developm
ent and w
ider availability, open initiatives for ventilators 
[86] 
IP Challenges 
IP im
itation and risk of counterfeit products [42][43] 
 
1) Patent infringem
ent law
suits 
attem
pts delaying  developm
ent of 
testing by existing players (e.g., 
law
suit by  Labrador D
iagnostics 
LLC
 against B
ioFire) [44] 
1) D
eclining access to existing C
risis-C
ritical IP m
ay lead to reverse - engineering 
by new
 entrants from
 non C
C
-Sectors (e.g., Italian volunteers 3D
 print reverse-
engineered valves after denial of IP)[29].  
2) Patents as barriers to the production and provision of low
-priced treatm
ents [74] 
M
onopoly over  C
C
-IP m
ay increase production cost of the C
O
V
ID
-19 related m
edicines and in turn the price. Proactive m
easures by governm
ents is the im
plem
entation of com
pulsory licensing [74] 
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  Table 2b IP Considerations for IP A
ssets and IP Strategies 
C
O
V
ID
-19 
Prevention 
D
iagnostics 
Treatm
ent 
How? 
IP Assets and Strategies 
IP Assets 
D
esigns (D
IY
 m
asks, hand free door handle attachm
ent) [66][70] 
Patents (e.g. vaccination related) 
Patents for testing technology 
D
esigns for test-kits 
Patents (e.g., drug related patents including product and process patents, patents of 
technologies for m
edical equipm
ent like ventilators, valves); N
ew
 patents (e.g., 
Isinnova plans to patent C
harlotte V
alve) [29] 
 
C
opyrights - free copyright (open access articles) provides access to relevant, know
ledge and research w
hich w
ould otherw
ise be not available [37], [80], [81] 
 
Which IP strategies are best suited to help achieve 
the IP purpose? 
1) O
pen source design for m
asks. (e.g., G
EN
TL m
ask, an open source 
design by EPA
M
 [65]) 
 2) Free access for lim
ited tim
e (e.g., IT giants G
oogle &
 M
icrosoft 
providing free access to their conference tools to support rem
ote w
orking) 
[13] 
 3) B
ilateral collaborations for vaccine developm
ent (e.g., Sanofi w
ith 
Translate B
io; G
SK
 w
ith C
lover) [18], [87] 
 4) C
onsortia for vaccine R
&
D
 [84] 
1) R
oyalty free licensing of patent-
protected diagnostics technology 
(e.g., Labrador D
iagnostics, a 
subsidiary of Fortress Investm
ent 
G
roup)[45] 
C
om
pulsory licensing: 
1) C
om
pulsory licensing for C
O
V
ID
-19 treatm
ent drugs (e.g. C
anada, C
hile, 
Israel) [74] 
 Free access: 
2) O
btaining new
 patent protection and giving the patent free for others to use [88]; 
free access and usage rights to existing patents [85] [50] 
 M
ulti sector collaboration: 
3) M
ulti-sector consortia to accelerate ventilator production to address dem
and-
supply shortage. E.g., V
entilator C
hallenge U
K
 consortium
 involving aerospace, 
autom
otive and m
edical industry players  [22] 
4) R
&
D
 in non-C
C
-Sectors to apply expertise from
 non C
C
-Sectors to develop 
m
edical equipm
ent (e.g., D
yson's C
oV
ent applying D
yson's air purifier expertise to 
develop ventilators) [78] 
1) V
oluntary pool by governing bodies (e.g., W
H
O
 asked to create voluntary pools  [39]) 
2) C
onsortia am
ong big pharm
a com
panies to accelerate the developm
ent, m
anufacture and delivery of vaccines, diagnostics, and treatm
ents for C
O
V
ID
-19' [89] 
3) Pledge to give free access to all C
C
-IP for lim
ited tim
e. V
oluntarily or through third-party platform
s (e.g., O
pen C
ovid pledge) [52], [53] 
4) H
ackathons to share and generate ideas [90] 
5) O
pen Platform
 Sharing of D
atasets and Source C
ode [91] 
  Table 3 V
accine D
evelopm
ent Sam
ple, total of 54 V
accines (2 in phase 1 clinical trials and 52 in pre-clinical)* 
Platform
 
Type of C
andidate V
accine 
D
eveloper 
C
linical Evaluation Stage 
Platform
 (non-C
oronavirus) 
1   Non- R
eplicating V
iral V
ector  
A
denovirus Type 5 V
ector  
C
anSino B
iological Inc. and  
B
eijing Institute of B
iotechnology  
Phase 1 ; C
hiC
TR
2000030906  
Ebola  
2   RN
A
  
LN
P- encapsulated m
R
N
A
  
M
oderna/N
IA
ID
  
Phase 1 ; N
C
T04283461  
m
ultiple candidates  
3   DN
A
  
D
N
A
 plasm
id vaccine  
Electroporation device  
Inovio Pharm
aceuticals  
Pre-C
linical  
Lassa, N
ipah, H
IV
, Filovirus, H
PV
, 
C
ancer indications, Zika, H
epatitis B 
4   DN
A
  
D
N
A
  
Takis/A
pplied D
N
A
 Sciences/Evvivax  
Pre-C
linical 
  
5   DN
A
  
D
N
A
 plasm
id vaccine 
Zydus C
adila 
Pre-C
linical  
 - 
6   Inactivated  
Inactivated + alum
  
Sinovac  
Pre-C
linical  
SA
R
S  
7   Inactivated  
Inactivated  
B
eijing Institute of B
iological Products/W
uhan  
Institute of B
iological Products  
Pre-C
linical  
 - 
8   Live A
ttenuated V
irus  
D
eoptim
ized live attenuated vaccines  
C
odagenix/Serum
 Institute of India  
Pre-C
linical  
H
A
V
, InfA
, ZIK
V
, FM
D
, SIV
, R
SV
, 
D
EN
V
  
9   Non- R
eplicating V
iral V
ector  
M
V
A
 encoded V
LP  
G
eoV
ax/B
ravoV
ax  
Pre-C
linical  
LA
SV
, EB
O
V
, M
A
R
V
, H
IV
  
10   Non- R
eplicating V
iral V
ector  
A
d26 (alone or w
ith M
V
A
 boost)  
Janssen Pharm
aceutical C
om
panies  
Pre-C
linical  
Ebola, H
IV
, R
SV
  
N
ote: *D
RAFT landscape of C
O
VID
-19 candidate vaccines, U
RL: https://w
w
w
.w
ho.int/blueprint/priority-diseases/key-action/N
ovel_C
oronavirus_Landscape_nC
oV_M
ar26.PD
F, last accessed [26.03.2020] 
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Fourthly, we see companies that possess a set of particular 
skills so they can be agile to speedily develop basically any kind 
of complex product, often possessing fairly flexible 
manufacturing facilities and equipment, but are often limited to 
low volume production. Examples include formula one teams, 
such as Williams Racing and McLaren that joined the UK 
ventilator challenge consortium [12]. 
 
All of these four types of companies typically own formal IP. 
These firms, being mostly large, commonly operate their own 
inhouse IP departments, thus possess awareness of IP relevance 
and understanding of how IP functions. However, their own IP 
which they developed before the start of the pandemic might 
not be exactly relevant in the CC-Sectors. 
 
When entering CC-Sectors to support the scaling up of CC-
Product manufacturing, these new entrants need to understand 
quickly how they can start manufacturing CC-Products in large 
volume. Essentially, to do this they have three options with 
regards to IP.  
 
The first option is not to worry (and care) about incumbents 
CC-IP and go ahead, thus (wilfully) infringing existing CC-
Products by reverse-engineering incumbent CC-Product.  
Under these circumstances, the owners of CC-IP may deny 
access to the proprietary information and know-how e.g., Italian 
3D printing volunteers were denied access to proprietary 
information about ventilator valves forcing them to reverse-
engineer the design [29] or in some cases enforce their IP and 
pursue the new entrants for infringement. So far this has been 
rare e.g. the case of Labrador Diagnostics LLC as previously 
mentioned, which is understandable during a pandemic due to 
potential reputational damages. However, new entrants 
choosing this option might become future targets for 
infringement claims from incumbents once the pandemic has 
ended. While new entrants are often large firms that can 
repurpose large manufacturing units, also well-established 
SMEs enter the production of CC-Products, e.g. local 
distilleries starting to produce sanitisers [24], [67]; 3D printing 
companies producing PPE [95]. Given their small scale, they 
might not be particularly prone to be attacked by incumbent IP 
owners but they would be in a vulnerable position if that 
situation did arise. 
 
The second option for new entrants is to start designing CC-
Products from scratch, possibly using their own engineering 
design competence and ability to procure rapid expert advice. 
For example, Dyson’s ventilator design Covent, which was 
developed in partnership with MedTech consultancy. The 
Technology Partnership (TTP) [78]. Other efforts are being led 
by coalitions of large technology consultancies such as 
Cambridge Consultants, who typically work on medical device 
projects for clients but without holding their own IP [96]. 
However, starting from the ground up might not be the most 
efficient way to achieve impact during a pandemic as 
developing and obtaining medical approval for new CC-
Product designs is likely to cause further delays. Choosing this 
option, new entrants would essentially develop novel CC-IP. 
However, if not carrying out careful freedom to operate 
analysis, they may infringe on existing background CC-IP 
owned by incumbents. Carrying out freedom to operate analysis 
may further delay the quick manufacturing of CC-Products. So 
new entrants are left balancing these risks under uncertainty and 
rapid changes to the technological, regulatory, economic and 
legal landscape. 
 
The third option is to access CC-IP through teaming up with 
incumbents to produce some of the existing CC-Products 
manufactured prior to the pandemic by the incumbents only. 
For instance, the Smiths group and Penlon are incumbents with 
own ventilator designs who joined the UK ventilator challenge 
consortium [97]. These companies can then grant licenses and 
share CC-IP with consortium partners, including new entrants. 
Other incumbents, e.g. Medtronic, selectively pledged CC-IP 
for their Puritan BennettTM 560 - a basic ventilator model for 
which they have made available all designs and manufacturing 
details under a permissive license for a limited term [50]. For 
new entrants to access CC-IP this way is a way to avoid 
infringing existing IP owned by incumbents. For incumbents to 
pledge CC-IP is a way to facilitate the adoption of their 
technology during the pandemic, potentially with some lasting 
benefits beyond the pandemic. For instance, they can share CC-
IP during a pandemic freely without charging any royalties 
using licenses that are time limited. If companies want to 
continue using that IP beyond the pandemic, the licensing terms 
would either prevent that or these companies would have to pay 
royalties.  
 
Whether new entrants start developing designs for CC-
Products from scratch, license existing CC-IP or infringe upon 
existing CC-IP, when scaling up production using their own 
resources new entrants are likely to develop novel (foreground) 
CC-IP. Given that they are faced with resource constraints 
having to manufacture CC-Products with equipment at their 
disposal and with materials they can access quickly through 
existing supplier relationships, they very well may end up 
adapting existing designs. This may lead them to find inventive 
designs or ways to e.g. manufacture CC-Products in a cheaper 
way. New entrants could possibly consider formally registering 
this new CC-IP, e.g. by filing patents.  
 
Suddenly, incumbents may find themselves confronted with 
new entrants in their sector that infringe their CC-IP to some 
extent, which they find difficult to enforce during a pandemic, 
with new entrants developing subsequently their own CC-IP. 
Incumbents may fear that some of the new entrants will 
continue to stay in ‘their’ sectors i.e., CC-Sectors even after the 
pandemic eventually ends. Having established capabilities to 
manufacture CC-Products in innovative ways or using 
innovative designs e.g. low cost version for less developed 
countries, these new entrants may have few incentives to stop 
producing CC-Products and exit CC-Sectors. Incumbents may 
find themselves having helped to establish new competitors by 
not enforcing CC-IP during a pandemic. The extent to which 
this is a concern will depend on the incumbent’s existing 
business model and IP strategy and their interaction strategy 
with the new entrants, therefore it is difficult to predict at 
present the severity of concern or whether it is justified. 
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B. Scenario 2: Type 2 New Entrants - Voluntary Grassroot 
Initiatives, not-For Profit Organisations, Start-ups 
 
During the past weeks we observed a large number of newly 
launched voluntary grassroots initiatives, not-for-profit 
organisations and start-ups joining the development and 
production of CC-Products. These initiatives often adopt 
explicitly or implicitly open source approaches widely sharing 
their designs. It seems we can distinguish two categories of such 
initiatives.  
 
First, we have seen that a number of highly innovative 
voluntary initiatives got active to help with developing and 
manufacturing CC-Products. Those are typically founded by 
highly skilled people, such as engineers and scientists, and often 
develop fairly complex (high-tech) CC-Products, including 
hardware for ventilators, but also data platforms to collate 
pandemic data or tracking applications. For instance, a large 
number of institutions have developed complex 
epidemiological models, and geospatial models to understand 
the spread and development of the virus together with 
behaviour science, as well discuss the different approaches that 
have been used by governments (non-medical interventions) to 
slow the pandemic [32]. An important development is the 
utilisation of Artificial Intelligence (AI) methodologies, and 
specifically Deep Convolutional Neural Networks to detect 
COVID-19 from X-Ray images, as well as to identify the 
development and stage of the disease.  
 
Quickly, several initiatives have come up with stunning new 
and affordable, easy to produce CC-Product designs which have 
often undergone highly sophisticated testing with state of the 
art equipment to which scientists have access through their labs. 
The initiatives then typically share their design drawings, CAD 
files as well as testing data through open source approaches, 
either through formal adoption of open source hardware and 
software licences or informally through statements of intent.  
 
While these initiatives develop novel foreground CC-IP, they 
typically build on existing designs and by then adopting 
outbound licensing / open IP approaches [98], there is a 
potential (residual) risk that their designs may actually infringe 
upon existing CC-IP. As those initiatives usually have limited 
IP expertise and lack resources to access external legal support 
(e.g. patent attorneys), it is unlikely that most initiatives 
conduct freedom to operate analysis before launching their 
novel CC-Products. This lack of due diligence and IP clearance, 
with the open source initiatives probably excluding any 
liabilities and warranties for their designs, could lead any 
industrial adopter starting to produce an open source design in 
volume into trouble, suddenly unwillingly infringing 
incumbent CC-IP. 
 
The second category includes the various initiatives that 
focus on the redesign or new manufacturing approaches for 
‘low-tech’ CC-Products, i.e. with low technical and 
manufacturing complexity. Those CC-Products include face 
masks where we have seen numerous initiatives releasing 
patterns online calling for home production, i.e. crowd-
manufacturing. Most of these initiatives might not be seen as 
highly innovative from an industrial standpoint as they produce 
fairly mature and ‘dated’ CC-Products, which might not be 
protected anymore by any alive IP. For instance, patents that 
once protected face mask designs may have long expired. 
 
However, various initiatives focusing on low-tech CC-
Products clearly innovate developing novel solutions that go 
beyond existing CC-Products. For instance, different initiatives 
have started to develop new face shield designs that are 
optimised for 3D printing. Those initiatives develop potentially 
patentable novel CC-IP, while not necessarily infringing 
incumbent owned CC-IP as this has probably already expired. 
Overall, those initiatives may not run into particular 
infringement risks, however, are likely to create novel 
foreground CC-IP. Given that most initiatives adopt open 
source licensing approaches they may not formally seek to 
protect their novel CC-IP through filing patents. However, we 
can possibly expect to see some trademark registrations 
appearing from some of the initiatives that become 
commercially viable, e.g. those also starting mass 3D printing 
production of face shields in Lithuania [99].  
 
C. Scenario 3: Incumbents 
 
Certain expertise like vaccine and drug development are so 
unique to the incumbents in CC-Sectors that new entrants are 
less or almost unlikely to contribute significantly within the 
short time frames available during a pandemic. In these cases, 
incumbents in CC-Sectors developing new solutions or 
contributing to upscaling may end up infringing CC-IP of other 
incumbents. Our analysis shows that incumbents may take one 
or more of the following three approaches, each coming with 
different IP considerations.  
 
One approach is the development of new technologies and 
solutions based on their pre-pandemic technologies and their 
expertise unique to CC-Sectors, thereby independently creating 
innovative novel CC-IP within their expertise. An example is 
the COVID testing developed by BioFire claimed to be based 
on its existing technologies (e.g. BioFire Filmarray). A second 
approach is that CC-Sector incumbents who were pre-pandemic 
component suppliers suddenly establish large scale 
manufacturing units to address supply-shortages. An example 
is INEOS, a chemical giant, supplier of one of the key 
ingredients used in sanitisers, established huge manufacturing 
capacities in France to produce about 1 million bottles per 
month. The third approach requires incumbents to collaborate 
by forming bilateral collaborations (e.g., agreement between Eli 
Lilly and AbCellera), establish new consortia (e.g., 
OPENCORONA consortium [84], COVID-19 Therapeutics 
Accelerator [82]) or joining existing networks (e.g., CEPI 
(Coalition for Epidemic Preparedness Innovations) and 
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Europe’s IMI (Innovative Medicines Initiative) [89]) and share 
IP among themselves to accelerate the efforts. The consortiums 
are likely to include non-commercial entities such as 
universities and research centres. Our analysis shows that 
consortiums at the prevention stage focus mainly on vaccine 
development. Examples include Horizon 2020’s 
OPENCORONA consortium [84], consortium among Novartis, 
Bristol Myers Squibb and GSK [19], ChAdOx1 consortium 
involving universities and research centres. For treatment, 
consortiums are for CC-Products (e.g., UK Ventilator 
Challenge consortium [12]) and drugs (e.g., see [89] for several 
of R&D efforts by incumbents).  
 
Two CC-IP considerations can be identified in the three 
approaches taken by incumbents. First, in the efforts by 
incumbents to accelerate CC-Product development, they may 
not conduct freedom to operate analysis as it is time taking. So, 
they may end up facing infringement lawsuits by other 
incumbents owning similar CC-IP (e.g., Labrador Diagnostics 
LLC’s lawsuit against BioFire [100]). Second, when pre-
pandemic suppliers establish mass production and 
manufacturing units, they might generate foreground IP during 
a pandemic, and would like to stay in the market post pandemic 
as well. 
 
To summarise (Fig. 4), new entrants rushing to help the large 
scale production of high-tech CC-Products (e.g. ventilator 
production, diagnostic kits), particularly large ones entering 
CC-Sectors might be more at a risk to infringe active / alive CC-
IP owned by incumbents than those entering low tech CC-
Products, for which formally relevant IP might have already 
expired (e.g. face masks) or free alternatives exit. Overall, large 
firms might be more at risk to become targets for future (i.e. 
after the pandemic) infringement claims than SMEs and 
voluntary initiatives. A particular consideration that should be 
mentioned is that while rushing into CC-Product manufacturing 
large firms may not perceive IP to be that urgent given a current 
crisis, which could turn out to be difficult in the long run as this 
could come with considerable IP risks. Incumbent owners of 
CC-IP might have a lower probability to sue voluntary 
initiatives, because they cannot claim damages, so could only 
ask for injunctions, which may cause themselves reputational 
damages. An exception might be the case of a CC-Product 
developed by a voluntary initiative, which is then produced in 
large volumes. However, a voluntary initiative giving away its 
IP open source would not make sufficient money to be a 
damage claim target. Rather those manufacturing an open 
source design without a clean freedom to operate situation 
could be targets for infringement claims. One also has to 
consider that new entrants, whether large manufacturing firms 
or voluntary initiatives, are likely to develop novel CC-IP 
during a pandemic, which they could use when continuing to 
stay in CC-Sectors.  
 
V. APPROACHES TO ADDRESS CRISIS RELATED  
IP CHALLENGES 
 
A pandemic is characterised as a crisis that calls for urgent, 
imminent large-scale action by governments, industrial players 
as well as a range of other societal actors. Governments take 
centre stage to orchestrate the rapid response to a pandemic. 
One of their many primary concerns is enabling the large scale 
production of Crisis-Critical Products (CC-Products), with the 
demand typically far exceeding the manufacturing capacities 
Fig. 4 Crisis-Critical IP (CC-IP) during a Pandemic 
Crisis-Critical Intellectual Property: Considerations during the COVID-19 Pandemic       © F. Tietze, P. Vimalnath, L. Aristodemou, J. Molloy 14 
available from incumbent manufacturers in Crisis-Critical 
Sectors (CC-Sectors). This then calls for other firms to enter 
CC-Sectors and support the mass manufacturing of CC-
Products by repurposing manufacturing lines. This leads to 
situations where manufacturing firms find themselves suddenly 
engaged in new relationships (e.g. UK ventilator challenge 
[22]), possibly even with companies that were competitors 
before the pandemic. 
 
A pandemic, such as exemplified by the current COVID-19 
crisis, also leads to wide ranging innovation activities, whether 
by incumbents or new entrants, being large firms themselves or 
various grassroot initiatives, not-for-profit organisations or 
start-ups etc. While governments’ priority must be to enable the 
mass production of CC-Products, they should not forget to 
address potential IP concerns that incumbents or new entrants 
may have and think about ways to reduce IP related risks. At 
least three possible approaches are available to support the 
reduction of IP associated risks.  
 
One legal approach that most governments have stems from 
the TRIPS agreement. Compulsory licensing is a tool that 
governments have in those countries that have adopted TRIPS 
[101]. It allows governments to use IP in crisis situations such 
as the COVID-19 pandemic. However, compulsory licenses are 
typically seen as a last resort measure. Compulsory licensing 
particularly helps governments to access and use CC-IP and 
thereby reduce IP associated risks mostly to new entrants, but 
are usually not favoured by incumbents, even though 
governments typically have to agree to pay a reasonable royalty 
for accessing their IP. In the current pandemic, countries that 
have already considered compulsory licensing with more to be 
expected include Chile, Canada and Israel [40], [41], [102].  
 
Another, voluntary approach is to call owners of CC-IP 
(mostly incumbents) to pledge [48], [98], [103] their IP so that 
new entrants get non-exclusive licenses to use incumbents’ CC-
IP at least for the duration of the pandemic. Examples include 
firm specific pledges, e.g. by Medtronic [104], AbbVie [85] and 
SMITHS [105], but also the Open COVID Pledge 
(www.openCOVIDpledge.org) [52], [53] for industrially 
relevant IP as well as the Wellcome Trust pledge [36] for 
research publications and datasets. The pledge option, 
particularly with a time limited license, appears to be more 
friendly to incumbents while also de-risking IP challenges for 
new entrants. Pledges often also provide license templates that 
others can use and adjust to their needs.  
 
Another approach to reduce IP associated risks and thus 
avoid any delays in fighting a pandemic are CC-IP pools, which 
can then be made available to a restricted group of companies 
(e.g., a consortium) only or to all interested firms that want to 
use that IP. A formal approach for governments would be to 
facilitate the development of patent pools [106], which have 
already been used in the pharmaceutical industry (e.g. 
Medicines patent pool).  
VI. CONCLUSIONS 
 
Coronavirus is a virus family to which belongs the virus 
causing COVID-19. This paper shows that research and IP 
protections for coronavirus related inventions is not new. Patent 
protection for different forms of coronavirus already exist but 
not for the particular coronavirus type, SARS-CoV-2 that 
causes the COVID-19 disease. It is also evident that there is a 
time-lag between the outbreak and the materialisation of 
patents, and high number of citations to Non-Patent Literature, 
which shows the urgency of scientists for open data to put the 
information in the public domain.  
 
What makes it difficult for IP to be given its required 
considerations during the early stage of a pandemic is the 
enormous sense of urgency which easily draws decision makers 
attention to huge and undoubtedly urgent operational 
challenges. With this paper we hopefully contribute to raising 
awareness that IP needs to be dealt with rather earlier than later 
during a pandemic in order to avoid that IP associated risks 
delay the mobilisation of resources so urgently needed for the 
research, development and mass manufacturing of Crisis-
Critical Products.  
 
This paper provides a terminology that helps to conceptualise 
IP considerations in times of a pandemic or global crisis that 
calls for urgent and large-scale actions from industrial 
stakeholders that suddenly find themselves engaged in new 
relationships that are associated with various uncertainties, not 
the least related to the use and sharing of IP with the particular 
problem that negotiating licensing agreements is typically time 
consuming. 
 
From analysing the currently unfolding COVID-19 
pandemic, we identify IP associated challenges relating to the 
prevention, diagnosis and treatment of a pandemic. We identify 
four types of stakeholders that are mostly concerned with IP 
considerations. These include governments (and inter-
governmental organisations, such as the WHO, WIPO) who are 
called upon to orchestrate pandemic responses, incumbent 
manufacturing firms in CC-Sectors as well as new entrants that 
enter Crisis-Critical Sectors to assist incumbents. These new 
entrants can be manufacturing firms that have not produced 
Crisis-Critical Products prior to a pandemic, but also voluntary 
grassroot initiatives, start-ups, entrepreneurial scientists, etc.  
 
We identify and analyse three scenarios in which different 
considerations around IP emerge. In the first scenario 
manufacturing firms enter Crisis-Critical Sectors to assist 
incumbents in mass manufacturing the volume required of 
Crisis-Critical Products. Those firms possess complementary 
capabilities and resources, so they can repurpose production 
lines. In the second scenario we discuss IP considerations when 
voluntary grassroot initiatives enter Crisis-Critical Sectors. In 
the third scenario we discuss R&D and manufacturing 
engagements and IP considerations for the incumbents in the 
CC-Sectors. We finally provide an initial discussion of three 
possible approaches to address IP concerns during a pandemic, 
namely compulsory licensing, IP pledges and IP pooling. 
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